Sight Sciences (SGHT) Competitors $3.27 -0.06 (-1.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.28 +0.00 (+0.15%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGHT vs. IRMD, SIBN, BBNX, EMBC, SMLR, CBLL, KIDS, AVNS, BVS, and AXGNShould you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include iRadimed (IRMD), SiBone (SIBN), Beta Bionics (BBNX), Embecta (EMBC), Semler Scientific (SMLR), CeriBell (CBLL), OrthoPediatrics (KIDS), AVANOS MEDICAL (AVNS), Bioventus (BVS), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry. Sight Sciences vs. Its Competitors iRadimed SiBone Beta Bionics Embecta Semler Scientific CeriBell OrthoPediatrics AVANOS MEDICAL Bioventus AxoGen iRadimed (NASDAQ:IRMD) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Which has preferable valuation & earnings, IRMD or SGHT? iRadimed has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRadimed$73.24M11.49$19.23M$1.5542.69Sight Sciences$79.87M2.12-$51.51M-$0.98-3.34 Is IRMD or SGHT more profitable? iRadimed has a net margin of 26.33% compared to Sight Sciences' net margin of -63.24%. iRadimed's return on equity of 23.28% beat Sight Sciences' return on equity.Company Net Margins Return on Equity Return on Assets iRadimed26.33% 23.28% 20.59% Sight Sciences -63.24%-54.62%-34.92% Does the media refer more to IRMD or SGHT? In the previous week, iRadimed had 7 more articles in the media than Sight Sciences. MarketBeat recorded 10 mentions for iRadimed and 3 mentions for Sight Sciences. iRadimed's average media sentiment score of 0.63 beat Sight Sciences' score of 0.18 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, IRMD or SGHT? iRadimed has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.45, meaning that its share price is 145% more volatile than the S&P 500. Do analysts recommend IRMD or SGHT? iRadimed currently has a consensus target price of $72.00, indicating a potential upside of 8.81%. Sight Sciences has a consensus target price of $3.93, indicating a potential upside of 20.29%. Given Sight Sciences' higher possible upside, analysts plainly believe Sight Sciences is more favorable than iRadimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRadimed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sight Sciences 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29 Do insiders & institutionals have more ownership in IRMD or SGHT? 92.3% of iRadimed shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 36.8% of iRadimed shares are owned by insiders. Comparatively, 30.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryiRadimed beats Sight Sciences on 12 of the 16 factors compared between the two stocks. Get Sight Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGHT vs. The Competition Export to ExcelMetricSight SciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.15M$6.77B$5.47B$9.53BDividend YieldN/A1.32%4.74%4.08%P/E Ratio-3.3420.9428.6723.80Price / Sales2.1259.01422.2688.08Price / CashN/A20.5035.4557.96Price / Book1.904.468.275.55Net Income-$51.51M$174.54M$3.24B$259.03M7 Day Performance-6.30%-5.27%-3.63%-4.56%1 Month Performance-21.39%-3.94%4.40%4.49%1 Year Performance-48.18%8.26%25.97%18.05% Sight Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGHTSight Sciences2.0728 of 5 stars$3.27-1.8%$3.93+20.3%-55.9%$172.15M$79.87M-3.34210High Trading VolumeIRMDiRadimed4.1857 of 5 stars$56.19-0.9%$72.00+28.1%+43.4%$720.81M$75.15M36.25110News CoverageEarnings ReportDividend AnnouncementGap UpSIBNSiBone3.9258 of 5 stars$16.67+0.3%$22.50+35.0%+17.2%$708.25M$167.18M-26.05350Upcoming EarningsBBNXBeta Bionics2.3438 of 5 stars$14.30+5.2%$23.44+63.9%N/A$589.21M$65.12M0.00294Trending NewsEarnings ReportAnalyst ForecastLockup ExpirationAnalyst RevisionGap DownEMBCEmbecta4.6464 of 5 stars$10.29+5.2%$19.00+84.6%-35.3%$571.57M$1.12B11.432,100News CoverageUpcoming EarningsSMLRSemler Scientific2.5482 of 5 stars$39.67-3.8%$89.00+124.4%+14.4%$568.63M$56.29M-15.20120Upcoming EarningsGap DownCBLLCeriBell2.2299 of 5 stars$15.21-2.4%$32.14+111.3%N/A$563.11M$65.44M0.00N/AKIDSOrthoPediatrics3.7468 of 5 stars$21.88-0.6%$35.83+63.8%-33.2%$534.56M$212.45M-12.50200News CoverageUpcoming EarningsAVNSAVANOS MEDICAL2.3241 of 5 stars$11.40+1.6%N/A-53.7%$518.86M$687.80M-1.362,227News CoverageUpcoming EarningsBVSBioventus3.1467 of 5 stars$6.30+0.6%$13.75+118.3%-11.7%$517.51M$567.70M-10.331,200AXGNAxoGen2.3587 of 5 stars$11.61+2.9%$24.50+111.0%+55.3%$513.74M$194.52M-77.39450Upcoming Earnings Related Companies and Tools Related Companies IRMD Alternatives SIBN Alternatives BBNX Alternatives EMBC Alternatives SMLR Alternatives CBLL Alternatives KIDS Alternatives AVNS Alternatives BVS Alternatives AXGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGHT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sight Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
